Market Place
Sourcing Support
Positive Results In The Interim Analysis Of The Trial Of Recbio`s Vaccine REC610
28 Dec 2023 //
PR NEWSWIRE
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report
27 Aug 2023 //
PR NEWSWIRE
Acceptance of Clinical Trial Application For The Recbio`s Vaccine REC610
26 Jul 2023 //
PR NEWSWIRE
Two-Component Recombinant COVID-19 Vaccine ReCOV Granted With EUA
21 Mar 2023 //
PR NEWSWIRE
Clinical Trial Approval For The Company`s Novel Vaccine REC610
19 Dec 2022 //
PRNEWSWIRE
Superior Results Of The Comparative Study Of Recombinant COVID-19 Vaccine ReCOV
14 Dec 2022 //
PRNEWSWIRE
Jiangsu Recbio Increases Production For First Phase Of Manufacturing Facility
21 Nov 2022 //
PRNEWSWIRE
Recbio taps OCT Clinical for COVID-19 vaccine trial
13 Sep 2022 //
FIERCEBIOTECH
Recbio Announces Interim results for the Fiscal Year 2022 and Company Progress
29 Aug 2022 //
PRNEWSWIRE
Completion Of Subject Enrollment And Vaccination For ReCOV And mRNA Vaccines
18 Aug 2022 //
PRNEWSWIRE
Recbio announces phase III trial progress of recombinant HPV 9-valent vaccine
11 Aug 2022 //
PHARMABIZ
Approval Of The Comparative Study Between ReCOV And mRNA Vaccines By FDA
02 Aug 2022 //
PRNEWSWIRE
Clinical Trial Approval For ReCOV In The PRC And The Overseas Clinical Trial
04 May 2022 //
PRNEWSWIRE
Successful Passing Of The EU Qualified Person Audit
11 Apr 2022 //
PRNEWSWIRE
Recbio Announces Proposed Listing on Main Board of Hong Kong Stock Exchange
21 Mar 2022 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.